Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 15/20 | 0.60 |
| ▸ | RARA | P10276 | 15/20 | 0.60 |
| ▸ | RARG | P13631 | 15/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12959653 | 0.83 | RARA (0.62) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL12632982 | 0.81 | RARB (0.60) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL2225102 | 0.81 | RARA (0.60) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL18970150 | 0.79 | RARA (0.58) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL16998447 | 0.78 | RARB (0.60) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL8511470 | 0.78 | RARB (0.64) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL16998817 | 0.78 | RARB (0.60) | RARBRARARARGRXRAABCB1 | |
| SCHEMBL8510992 | 0.77 | RARB (0.66) | RARBRARARARGRXRA | |
| SCHEMBL16998401 | 0.77 | RARG (0.42) | RARBRARARARGRXRA | |
| SCHEMBL12632665 | 0.76 | RARB (0.55) | RARBRARARARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012069852-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE | ALMAC DISCOVERY LIMITED (GB) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | RARB 4194/4885RARA 4373/4885RARG 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.